Jonathan Uy

853 total citations
24 papers, 532 citations indexed

About

Jonathan Uy is a scholar working on Infectious Diseases, Virology and Immunology. According to data from OpenAlex, Jonathan Uy has authored 24 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 8 papers in Virology and 7 papers in Immunology. Recurrent topics in Jonathan Uy's work include HIV/AIDS drug development and treatment (10 papers), HIV/AIDS Research and Interventions (9 papers) and HIV Research and Treatment (8 papers). Jonathan Uy is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), HIV/AIDS Research and Interventions (9 papers) and HIV Research and Treatment (8 papers). Jonathan Uy collaborates with scholars based in United States, Belgium and Germany. Jonathan Uy's co-authors include Dorothy McCabe, Michael Muenzberg, Robert Popovian, Hillel P. Cohen, David Chien, Tracy Lessor, Michael J. Kozal, Jennifer Chiarella, Birgitte B. Simen and Donnie McGrath and has published in prestigious journals such as PLoS ONE, Antimicrobial Agents and Chemotherapy and The Journal of Urology.

In The Last Decade

Jonathan Uy

23 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jonathan Uy United States	10	280	222	176	108	81	24	532
Rebekah Puls Australia	16	421 1.5×	425 1.9×	88 0.5×	11 0.1×	56 0.7×	26	639
Janet Nicotera United States	8	389 1.4×	266 1.2×	17 0.1×	17 0.2×	51 0.6×	12	515
Pavel Khaykin Germany	10	226 0.8×	195 0.9×	152 0.9×	6 0.1×	26 0.3×	30	530
Xien Gui China	13	361 1.3×	116 0.5×	38 0.2×	12 0.1×	23 0.3×	46	618
Denise Sutherland‐Phillips United States	7	493 1.8×	374 1.7×	86 0.5×	9 0.1×	51 0.6×	13	827
Trevor R. Scott United States	10	342 1.2×	257 1.2×	44 0.3×	4 0.0×	51 0.6×	12	615
Jeffrey S. Murray United States	13	355 1.3×	218 1.0×	31 0.2×	19 0.2×	10 0.1×	31	729
Steven G. Deeks United States	2	403 1.4×	331 1.5×	57 0.3×	11 0.1×	11 0.1×	2	636
Gil Lavie Israel	10	233 0.8×	120 0.5×	16 0.1×	28 0.3×	11 0.1×	29	512
Douglas Fink United Kingdom	10	102 0.4×	58 0.3×	61 0.3×	16 0.1×	9 0.1×	31	331

Countries citing papers authored by Jonathan Uy

Since Specialization

Citations

This map shows the geographic impact of Jonathan Uy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Uy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Uy more than expected).

Fields of papers citing papers by Jonathan Uy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Uy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Uy. The network helps show where Jonathan Uy may publish in the future.

Co-authorship network of co-authors of Jonathan Uy

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Uy. A scholar is included among the top collaborators of Jonathan Uy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Uy. Jonathan Uy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Armstrong, April W., Timothy Fitzgerald, Robert R. McLean, et al.. (2023). The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Advances in Therapy. 40(5). 2493–2508. 5 indexed citations

Armstrong, April W., Timothy Fitzgerald, Robert R. McLean, et al.. (2022). Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry. Dermatology and Therapy. 13(2). 629–640. 2 indexed citations

Armstrong, April W., Timothy Fitzgerald, Robert R. McLean, et al.. (2022). Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry. Dermatology and Therapy. 13(2). 487–504. 4 indexed citations

Bissonnette, Robert, Alice B. Gottlieb, Richard G. Langley, et al.. (2021). Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR. Drug Safety. 44(6). 699–709. 8 indexed citations

Walsh, Jessica A., Kristina Callis Duffin, Abby S. Van Voorhees, et al.. (2021). Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas’ Psoriasis Registry. Dermatology and Therapy. 12(1). 97–119. 4 indexed citations

Armstrong, April W., Kristina Callis-Duffin, Timothy Fitzgerald, et al.. (2021). 25696 Impact of guselkumab on quality of life and work productivity outcomes among patients with moderate-to severe plaque psoriasis in the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology. 85(3). AB66–AB66. 1 indexed citations

Armstrong, April W., Kristina Callis-Duffin, Timothy Fitzgerald, et al.. (2021). 26916 Effectiveness of guselkumab among patients with moderate-to-severe plaque psoriasis in the Corrona Psoriasis Registry. Journal of the American Academy of Dermatology. 85(3). AB122–AB122.

Uy, Jonathan, et al.. (2020). Trip Generation Study of a Shuttle Service System in Southville 7. Transportation research procedia. 48. 2844–2851. 1 indexed citations

Cohen, Hillel P., David Chien, Tracy Lessor, et al.. (2016). Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Advances in Therapy. 33(12). 2160–2172. 162 indexed citations

10.

Zhu, Li, Roger J. M. Brüggemann, Jonathan Uy, et al.. (2016). CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. The Journal of Clinical Pharmacology. 57(2). 235–246. 26 indexed citations

11.

Hellstrom, Wayne J.G., Jed Kaminetsky, Laurence Belkoff, et al.. (2015). Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study. The Journal of Urology. 194(2). 485–492. 24 indexed citations

12.

Johnston, Stephen S., Timothy Juday, Derek Espindle, et al.. (2013). Comparative Incidence and Health Care Costs of Medically Attended Adverse Effects among U.S. Medicaid HIV Patients on Atazanavir- or Darunavir-Based Antiretroviral Therapy. Value in Health. 16(2). 418–425. 7 indexed citations

13.

Napravnik, Sonia, Joseph J. Eron, Timothy R. Sterling, et al.. (2012). Outcomes of Second Combination Antiretroviral Therapy Regimens Among HIV-Infected Persons in Clinical Care: A Multicenter Cohort Study. AIDS Research and Human Retroviruses. 29(3). 574–580. 9 indexed citations

14.

McDonald, Cheryl, Jonathan Uy, Wenhua Hu, et al.. (2012). Clinical Significance of Hyperbilirubinemia Among HIV-1–Infected Patients Treated with Atazanavir/Ritonavir Through 96 Weeks in the CASTLE Study. AIDS Patient Care and STDs. 26(5). 259–264. 25 indexed citations

15.

Lataillade, Max, Jennifer Chiarella, Rong Yang, et al.. (2012). Virologic Failures on Initial Boosted-PI Regimen Infrequently Possess Low-Level Variants with Major PI Resistance Mutations by Ultra-Deep Sequencing. PLoS ONE. 7(2). e30118–e30118. 31 indexed citations

16.

Broder, Michael S., Eunice Chang, Tanya G. K. Bentley, Timothy Juday, & Jonathan Uy. (2011). Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States. Journal of Medical Economics. 14(2). 167–178. 10 indexed citations

17.

Uy, Jonathan, et al.. (2011). Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine. AIDS Care. 23(11). 1500–1504. 3 indexed citations

18.

Lataillade, Max, Jennifer Chiarella, Rong Yang, et al.. (2010). Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study. PLoS ONE. 5(6). e10952–e10952. 101 indexed citations

19.

Uy, Jonathan, Carl Armon, Kate Buchacz, Kathy Wood, & John T. Brooks. (2009). Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure. JAIDS Journal of Acquired Immune Deficiency Syndromes. 51(4). 450–453. 43 indexed citations

20.

Kozal, Michael J., Katherine Huppler Hullsiek, Rodger D. MacArthur, et al.. (2007). The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral-Naïve Participants Started on Three Different Antiretroviral Therapy Strategies. HIV Clinical Trials. 8(6). 357–370. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact